Largest CIDP Trial Offers Promising Results for Drug Combo
DENVER — When combined with rHuPh20, a recombinant DNA-derived human hyaluronidase, efgartigimod, promises a new treatment option for chronic inflammatory demyelinating polyneuropathy (CIDP) , according to the results of a phase 2 multinational trial, which were reported at the 2024 annual meeting of the American Academy of Neurology…
Read More
0
